Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | F2R | P25116 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6582811 | 1.00 | BCHE (0.41) | BCHETSHRALDH1A1PKMITGB3 | |
| SCHEMBL19550801 | 1.00 | BCHE (0.41) | BCHETSHRALDH1A1PKMITGB3 | |
| SCHEMBL26971791 | 0.83 | BCHE (0.56) | BCHETSHRALDH1A1PKMITGB3 | |
| SCHEMBL2600287 | 0.83 | BCHE (0.56) | BCHETSHRALDH1A1PKMITGB3 | |
| SCHEMBL13045996 | 0.80 | BCHE (0.43) | BCHETSHRALDH1A1PKMITGB3 | |
| SCHEMBL6991659 | 0.80 | ALDH1A1 (0.42) | BCHETSHRALDH1A1PKMITGB3 | |
| SCHEMBL3315913 | 0.80 | TSHR (0.62) | BCHETSHRITGB3ITGA2BF2R | |
| SCHEMBL2600258 | 0.79 | BCHE (0.39) | BCHETSHRALDH1A1PKMITGB3 | |
| SCHEMBL20837312 | 0.79 | MAPK8 (0.44) | ALDH1A1ITGB3ITGA2BLMNAMAPK1 | |
| SCHEMBL13999836 | 0.79 | BCHE (0.62) | BCHETSHRALDH1A1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12060357-B2 | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | MERCK SHARP & DOHME LLC (US) | 2024-08-13 | — | — | US | disclosed |
| US-20220220117-A1 | 9-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2022-07-14 | — | — | US | disclosed |
| EP-3452466-B1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2020-08-12 | — | — | EP | disclosed |
| WO-2019055750-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | Aduro Biotech, Inc. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-10150760-B2 | Compounds for use in preparing heterocyclic triazole agonists of the APJ receptor | AMGEN INC. (US) | 2018-12-11 | — | — | US | disclosed |
| US-20180222895-A1 | COMPOUNDS FOR USE IN PREPARING HETEROCYCLIC TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2018-08-09 | — | — | US | disclosed |
| US-9988369-B2 | Heterocyclic triazole compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170320860-A1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-11-09 | — | — | US | disclosed |
| US-8163775-B2 | Allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA SA (CH) | 2012-04-24 | — | — | US | disclosed |
| US-20120022108-A1 | ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2012-01-26 | — | — | US | disclosed |
| WO-2009017874-A9 | NOVEL CURCUMIN DERIVATIVES AND THEIR PHARMACEUTICAL USES THEREOF | UNIV ROCHESTER (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009023357-A2 | CURCUMIN DERIVATIVES AND THEIR USE AS RADIOPROTECTORS | UNIVERSITY OF ROCHESTER (US) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009017874-A2 | NOVEL CURCUMIN DERIVATIVES AND THEIR PHARMACEUTICAL USES THEREOF | UNIVERSITY OF ROCHESTER (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20070219187-A1 | Allosteric Modulators of Metabotropic Glutamate Receptors | ADDEX PHARMA SA (CH) | 2007-09-20 | — | — | US | disclosed |
| EP-1070708-B1 | Triazole derivatives | HOFFMANN LA ROCHE (CH) | 2004-01-14 | — | — | EP | disclosed |
| US-6265426-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | HOFFMANN-LA ROCHE INC. | 2001-07-24 | — | — | US | disclosed |
| EP-1070708-A1 | Triazole and imidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-01-24 | — | — | EP | disclosed |
| US-5919799-A | OVERCOMING RESISTANCE TO AN ANTI-NEOPLASTIC AGENT OR AN ENHANCER FOR THE EFFECT OF AN ANTI-NEOPLASTIC AGENT COMPRISING SAID ENHANCER FOR THE EFFECT OF AN ANTI-NEOPLASTIC AGENT | NIKKEN CHEMICALS CO., LTD. (JP) | 1999-07-06 | — | — | US | disclosed |
| EP-0816366-A1 | IMIDAZOTHIAZOLE COMPOUNDS | Nikken Chemicals Company, Limited (JP) | 1998-01-07 | — | — | EP | disclosed |
| US-4199588-A | TRANQUILIZERS, MUSCLE RELAXANTS, ANTICONVULSANTS | BOEHRINGER INGELHEIM GMBH (DE) | 1980-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219187-A1 | Allosteric Modulators of Metabotropic Glutamate Receptors | GRM5, GRM2, GRM1 | BCHE 855/4885TSHR 268/4885ALDH1A1 3593/4885 |
| US-20120022108-A1 | ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM2, GRM1 | BCHE 855/4885TSHR 268/4885ALDH1A1 3593/4885 |
| US-20220220117-A1 | 9-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | ADORA2A, ADORA2B, ADORA3 | BCHE 3801/4885TSHR 131/4885ALDH1A1 815/4885 |
| US-12060357-B2 | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | ADORA2A, ADORA2B, ADORA3 | BCHE 3801/4885TSHR 131/4885ALDH1A1 815/4885 |
| US-20180222895-A1 | COMPOUNDS FOR USE IN PREPARING HETEROCYCLIC TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, APLNR, GPR27 | BCHE 4453/4885TSHR 262/4885ALDH1A1 2981/4885 |
| US-10150760-B2 | Compounds for use in preparing heterocyclic triazole agonists of the APJ receptor | TBXA2R, APLNR, GPR27 | BCHE 4453/4885TSHR 262/4885ALDH1A1 2981/4885 |
| US-20170320860-A1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | TBXA2R, APLNR, AGTR1 | BCHE 4679/4885TSHR 225/4885ALDH1A1 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.